Eli Lilly has entered into a strategic partnership with Juvena Therapeutics, committing over $650 million in milestones to develop novel muscle-boosting drugs. Juvena's AI-driven platform will identify biologic candidates that enhance muscle regeneration and body composition. This alliance follows growing interest in preserving lean mass amidst the rise of GLP-1 therapies and aims to expand Lilly’s pipeline of muscle-targeted therapeutics for conditions such as myotonic dystrophy and obesity-related muscle loss.